35 results
8-K
EX-10.1
akdbyq m05xox8
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
424B5
2xs2c2
14 Feb 24
Prospectus supplement for primary offering
4:09pm
424B5
wta9b4os6453yetx5
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
EX-99.2
1iovu1rw
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-10.1
zyho9xduf cmg
29 Dec 23
Departure of Directors or Certain Officers
5:00pm
425
ll0bmpfqb58bqza oll
21 Sep 23
Business combination disclosure
4:03pm
8-K
rt67 r1pmpk9q673
21 Sep 23
Other Events
4:01pm
424B3
ip364ehg0dg v3he
28 Aug 23
Prospectus supplement
9:10am
S-4/A
b1q9l
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
S-4
q1a10 54ih33k99lq
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm